Berna Biotech Korea

Berna Biotech Korea, now operating as Janssen Vaccines Korea, is a prominent vaccine manufacturer and a subsidiary of Johnson & Johnson. The company was established through the acquisition of the vaccine business of Korea Green Cross by the Swiss firm Berna Biotech, which was later acquired by Crucell and subsequently by Janssen. It is globally recognized for its production of Quinvaxem, a fully liquid pentavalent vaccine that protects against five major childhood diseases. The company's manufacturing facility in Incheon, South Korea, serves as a critical hub for the global supply of vaccines, particularly for international health organizations like UNICEF and GAVI. In addition to pediatric combination vaccines, the company produces recombinant Hepatitis B vaccines and has played a role in the global production network for Janssen's COVID-19 vaccine. Berna Biotech Korea remains a key player in the South Korean biotechnology sector, focusing on high-quality biologics manufacturing and global health initiatives.